0001213900-22-007757.txt : 20220215 0001213900-22-007757.hdr.sgml : 20220215 20220214211620 ACCESSION NUMBER: 0001213900-22-007757 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220214 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220215 DATE AS OF CHANGE: 20220214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 22636715 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea155719-8k_inmedpharma.htm CURRENT REPORT
0001728328 false A1 0001728328 2022-02-14 2022-02-14 0001728328 dei:FormerAddressMember 2022-02-14 2022-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 14, 2022

 

 

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

 

 

British Columbia   001-39685   98-1428279

(State or Other Jurisdiction

of Incorporation)

  

(Commission File Number)

 

  

(IRS Employer

Identification No.)

 

InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.

Canada

   V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

   Name of each exchange
on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On February 14, 2022, the Company announced financial results for the second quarter of fiscal year 2022 which ended December 31, 2021.

 

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No.   Description
     

99.1

   News release, dated February 14, 2022
104  Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
     
Date: February 14, 2022 By: /s/ Bruce Colwill  
    Bruce Colwill
    Chief Financial Officer

 

 

2

 

 

 EX-99.1 2 ea155719ex99-1_inmedpha.htm NEWS RELEASE, DATED FEBRUARY 14, 2022

Exhibit 99.1

 

 

 

NASDAQ: INM

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

 

●Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sector
●Strengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseases
●Commercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022
●Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases

 

Vancouver, BC – February 14, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced financial results for the second quarter of fiscal year 2022 which ended December 31, 2021.

 

Conference Call & Webcast:

 

Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 2:00 PM Eastern Time

US/Canada Participant Toll-Free Dial-In Number: +1 (855) 605-1745

US/Canada Participant International Dial-In Number: +1 (914) 987-7959

Conference ID: 8645175

Webcast: https://edge.media-server.com/mmc/p/sa6ykfmv

 (*Webcast replay available for 90 days)

 

The Company’s full financial statements and related MD&A for the second quarter ended December 31, 2021, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

 

“We have entered a new phase of our corporate evolution, extending our rare cannabinoid focus beyond pharmaceutical drug development to include the growing health and wellness sector where, as an ingredient supplier, we are generating commercial revenues. We are very pleased with the progress of the integration of BayMedica’s operations and team into our on-going activities at InMed. Within a short timeframe since the acquisition, we have initiated sales of an additional rare cannabinoid, such that our portfolio now includes CBC and CBT. Furthermore, we have accelerated the scale-up manufacturing of additional high demand cannabinoids, including CBDV and THCV, towards commercial launch in the coming months”, says Eric A. Adams, InMed President & CEO.

 

“We are committed to further product launches in the immediate term to build out a robust suite of products to meet the needs of the rapidly evolving health and wellness sector. At the same time, our pharmaceutical drug development programs continue to advance in both preclinical and clinical studies and we continue to expand InMed’s intellectual property portfolio, supporting sequential growth opportunities to hit important milestones across all aspects of our business.”

 

 

 

 

Business Update

 

Commercial Activities - Building out a rare cannabinoid portfolio

 

On October 13, 2021, InMed completed the acquisition of BayMedica Inc. (“BayMedica”), creating an industry leader in the manufacturing and commercialization of rare cannabinoids. Management has worked diligently to ensure a successful integration with a primary goal of accelerating commercial activities including several product launches and driving wholesale B2B revenues within the consumer health and wellness sector.

 

In January 2022, InMed announced that it launched B2B sales of cannabicitran (CBT) into the health and wellness sector. CBT is the second rare cannabinoid in our commercial product portfolio in addition to cannabichromene (“CBC”). BayMedica leads the industry in manufacturing commercial-scale CBC.

 

Additionally, commercial-scale production of cannabidivarin (“CBDV”) is underway, with an expected launch in the coming months. Commercial scale-up of another highly anticipated non-intoxicating product, tetrahydrocannabivarin (“THCV”), is also underway with sales expected to commence in second calendar quarter of 2022.

 

Continuing to build out a robust product portfolio is a strategic priority and the Company currently has several additional high-value rare cannabinoids, including CBGV and CBL, in various stages of development and commercial manufacturing scale-up. Pipeline development is imperative to maintaining an early-mover status and to maintain cost leadership with regards to specific rare cannabinoids.

 

Manufacturing

 

With the acquisition of BayMedica, InMed has access to multiple advanced synthetic manufacturing approaches giving us the flexibility to select the most cost-effective method to produce rare cannabinoids of interest. Our three manufacturing approaches – chemical synthesis, biosynthesis and IntegraSyn™, can each produce high-quality, bio-identical cannabinoids in a consistent manner for different target markets.

 

The Company continues to work closely with a manufacturing and development collaborator, the Almac Group (UK), to further optimize the IntegraSyn™ manufacturing process to be GMP-ready for pharmaceutical quality production. The next step is to advance production to larger batch sizes in the first calendar quarter of 2022, with the aim of demonstrating larger-scale viability at our industry leading cannabinoid yield.

 

The Company continues to believe IntegraSyn™ will be a preferred method for pharmaceutical grade production and may dovetail with BayMedica’s manufacturing approaches, including biosynthesis and chemical synthesis, for the health and wellness sector. The integrated InMed / BayMedica scientific team has begun exploring other natural cannabinoids as well as proprietary cannabinoid analogs, together with their requisite manufacturing methods, for future development.

 

Pharmaceutical Development Programs

 

INM-755 for the treatment of Epidermolysis Bullosa (“EB”)

 

In September 2021, the Company announced it had commenced a Phase 2 clinical trial, named 755-201-EB, of INM-755 (cannabinol) cream in the treatment of EB, marking the first time cannabinol (“CBN”) had advanced to a Phase 2 clinical trial to be studied as a therapeutic option to treat a disease.

 

2

 

 

The 755-201-EB study is designed to enroll up to 20 patients. InMed will evaluate the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and wound healing over a 28-day treatment period. All four subtypes of inherited EB, EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome are eligible for this study.

 

The study is planned to include 13 sites across 8 countries including Austria, Germany, Greece, France, Italy, Israel, Serbia and Spain. Five clinical sites have been fully activated. Enrollment and patient treatment began in December 2021 and are expected to complete during the calendar year 2022.

 

INM-088 for the treatment of glaucoma 

 

On December 20, 2021, InMed announced that a peer-reviewed scientific article entitled “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma”, was published in Biochimica et Biophysical Acta (BBA), a leading international journal. 

 

The reported studies demonstrated that CBN was effective at providing neuroprotection to the retina ganglion cells and reducing intraocular pressure in glaucoma models, out-performing several other naturally occurring cannabinoids. InMed is continuing to develop a larger scale drug product manufacturing process for the ocular disease product, completing dose-ranging studies and conducting topline clinical study design work with its clinical research organization.

 

The Company is preparing for a pre-Investigational New Drug (“PIND”) meeting with the US Food and Drug Administration (“FDA”) in the coming weeks and expects to file regulatory applications in the first half of calendar year 2023, to initiate a human clinical trial.

 

Expanding patent portfolio - use of rare cannabinoid for neurodegenerative disease

 

On November 3, 2021, InMed filed an international patent application seeking commercial exclusivity for the potential treatment of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and others by demonstrating neuroprotection and enhanced neuronal function using a rare cannabinoid.

 

This Patent Cooperation Treaty (“PCT”) application, entitled “Compositions and Methods for Treating Neuronal Disorders with Cannabinoids”, specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection and promoting neurite outgrowth in a population of affected neurons.

 

Expanding InMed’s patent portfolio to include, in addition to CBN, an incremental rare cannabinoid for the potential treatment of major neurodegeneration indications demonstrates the Company’s continued commitment to its pharmaceutical drug development programs and the potential of rare cannabinoids in treating important diseases.

 

New Cannabinoid analogs

 

BayMedica has produced a library of novel cannabinoid analogs that present an opportunity for the Company to explore their therapeutic potential. These patentable analogs allow for the investment in the research and development of rare cannabinoids while ensuring the commercial protection of their long-term value. The analogs, which include slight modifications to naturally occurring cannabinoids, target specific properties and enhance biological function in a therapeutic model, may also enhance the safety profile, improve delivery, or combinations thereof.

 

3

 

 

Corporate

 

The Company is pleased to announce the appointment of Ms. Janet Grove to its Board of Directors, effective 11 February 2022.

 

Ms. Janet Grove is a Partner at Norton Rose Fulbright Canada LLP (“NRF”). She is highly sought after for her expertise and business approach to structuring and negotiating both merger and acquisition transactions and complex commercial relationships to develop, commercialize and acquire technology. Ms. Grove is currently the Canadian head of NRF’s life sciences and healthcare industry practice, is on the board of Genome BC and is a member of the Audit and Assurance Standards Council of Canada.  Ms. Grove was appointed as a Queen’s Counsel in British Columbia in 2000.

 

“We enthusiastically welcome Janet to our Board of Directors. Janet has significant skills and experience in providing strategic legal and business development advice built during an impressive 30+ year career in the biotech industry,” commented William Garner, InMed’s Chairman of the Board of Directors.

 

Contemporaneous with Ms. Grove’s appointment, Catherine Sazdanoff has decided to transition off the Board of Directors for personal reasons. Ms. Sazdanoff has served on the Board since July 2019, during which time her business development and legal experience has been instrumental in navigating several key strategic initiatives of the Company. Over the years, Ms. Sazdanoff has served as Chair of the Corporate Governance and Nominating Committee as well as a member of the Compensation Committee and Audit Committee.  On behalf of all stakeholders, we wish to thank Ms. Sazdanoff for her dedicated service to the Company.

 

Financing Activities and Results of Operations (expressed in US Dollars):

 

On October 13, 2021, the Company completed the acquisition of BayMedica. The Company acquired 100% of BayMedica in exchange for i) 2,050,000 common shares issued to BayMedica’s equity and convertible debt holders, subject to a six-month contractual hold period; and, ii) $1 million to be held in escrow, subject to reduction for certain post-closing adjustments or satisfaction of indemnification claims under the definitive agreement in the six- and twelve-month periods following the closing.

 

For the six months ended December 31, 2021, the Company recorded a net loss of $7.3 million, or $0.56 per share, compared with a net loss of $3.8 million, or $0.68 per share, for the six months ended December 31, 2020.

 

Research and development expenses were $4.0 million for the six months ended December 31, 2021, compared with $1.8 million for the six months ended December 31, 2020. The increase in research and development and patents expenses was primarily due to increased activities related to the INM-755 clinical trials and the inclusion of BayMedica operating results following the acquisition date. For the period from the acquisition date through December 31, 2021, research and development and patent expenses attributable to BayMedica were $0.6 million.

 

4

 

 

The Company incurred general and administrative expenses of $3.2 million for the six months ended December 31, 2021, compared with $1.6 million for the six months ended December 31, 2020. The increase results primarily from a combination of changes including personnel expenses, legal fees and investor relation expenses, substantially higher insurance fees resulting from our listing on the Nasdaq Capital Market which occurred during the three months ended December 31, 2020, and the inclusion of BayMedica operating results following the acquisition date.

 

At December 31, 2021, the Company’s cash, cash equivalents and short-term investments were $11.3 million, which compares to $7.4 million at June 30, 2021. The increase in cash, cash equivalents and short-term investments during the six months to December 31, 2021, was primarily the result of the July 2, 2021 private placement partially offset by cash outflows from operating activities.

 

At December 31, 2021, the Company’s total issued and outstanding shares were 14,137,034. During the three and six months ending December 31, 2021, the weighted average number of common shares was 13,847,360 and 12,923,324, which is used for the calculation of loss per share for the respective interim periods.

 

BayMedica Revenue

 

The Company realized net sales of $0.3 million for the three months ended December 31, 2021, the result of manufacturing and distribution sales of bulk rare cannabinoids following the acquisition of BayMedica in October 2021, and thus there were no comparable revenues in the 2020 period. The Company realized cost of goods sold of $0.2 million for the three months ended December 31, 2021, with no comparable expenses in 2020, resulting in a gross profit of $0.1 million for the period.

 

Reported sales were impacted this quarter by the inclusion of sales only from the acquisition date and as a consequence of BayMedica’s focus on the acquisition including post-closing integration matters. Prior to the acquisition, BayMedica had cumulative revenues of $2.4 million for the 21-month period ending September 30, 2021. With several new product launches planned in the coming months, the Company anticipates substantial revenue growth.

 

5

 

 

Table 1: Condensed Consolidated Interim Balance Sheets (unaudited):

 

As at December 31, 2021 and June 30, 2021

Expressed in U.S. Dollars

 

 

   December 31,   June 30, 
   2021   2021 
   $   $ 
ASSETS        
Current        
Cash and cash equivalents   11,279,964    7,363,126 
Short-term investments   45,424    46,462 
Accounts receivable   50,304    11,919 
Inventories   988,822    - 
Prepaids and other assets   140,512    956,762 
Total current assets   12,505,026    8,378,269 
           
Non-Current          
Property and equipment, net   1,096,649    326,595 
Intangible assets, net   2,400,831    1,061,697 
In-process research and development   1,249,000    - 
Goodwill   2,023,039    - 
Other assets   109,175    14,655 
Total Assets   19,383,720    9,781,216 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current          
Accounts payables and accrued liabilities   3,358,489    2,134,878 
Short-term debt   58,624    - 
Current portion of lease obligations   391,805    80,483 
Deferred revenue   8,390    - 
Acquisition consideration payable   800,457    - 
Total current liabilities   4,617,765    2,215,361 
           
Non-current          
Lease obligations   598,642    189,288 
Total Liabilities   5,216,407    2,404,649 
           
Shareholders’ Equity          
Common shares, no par value, unlimited authorized shares:          
14,137,034 (June 30, 2021 - 8,050,707) issued and outstanding   69,096,601    60,587,417 
Additional paid-in capital   27,049,042    21,513,051 
Accumulated deficit   (82,106,899)   (74,852,470)
Accumulated other comprehensive income   128,569    128,569 
Total Shareholders’ Equity   14,167,313    7,376,567 
Total Liabilities and Shareholders’ Equity   19,383,720    9,781,216 

 

6

 

 

Table 2: Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (unaudited):

 

For the three and six months ended December 31, 2021 and 2020

Expressed in U.S. Dollars

 

 

   Three Months Ended   Six Months Ended 
   December 31   December 31 
   2021   2020   2021   2020 
   $   $   $   $ 
                 
Sales   265,092    -    265,092    - 
Cost of sales   153,537    -    153,537    - 
Gross profit   111,555    -    111,555    - 
                     
Operating Expenses                    
Research and development and patents   2,537,070    937,948    4,028,322    1,849,104 
General and administrative   1,836,786    959,554    3,209,653    1,584,342 
Amortization and depreciation   49,797    36,816    78,329    64,797 
Total operating expenses   4,423,653    1,934,318    7,316,304    3,498,243 
                     
Other Income (Expense)                    
Interest income   4,222    3,050    9,370    7,395 
Finance expense   -    (360,350)   -    (360,350)
Unrealized gain on derivative warrants liability   -    242,628    -    242,628 
Other income   22,055    -    22,055    - 
Foreign exchange gain (loss)   3,007    (194,792)   (81,105)   (234,291)
Net loss for the period   (4,282,814)   (2,243,782)   (7,254,429)   (3,842,861)
                     
Other Comprehensive Loss                    
Foreign currency translation gain   -    301,043    -    430,443 
Total comprehensive loss for the period   (4,282,814)   (1,942,739)   (7,254,429)   (3,412,418)
                     
Net loss per share for the period                    
Basic and diluted   (0.31)   (0.37)   (0.56)   (0.68)
Weighted average outstanding common shares                    
Basic and diluted   13,847,360    6,091,359    12,923,324    5,656,033 

 

7

 

 

Table 3: Condensed Consolidated Interim Statements of Cash Flows (unaudited):

 

For the six months ended December 31, 2021 and 2020

Expressed in U.S. Dollars

 

 

   2021   2020 
   $   $ 
Cash provided by (used in):        
         
Operating Activities        
Net loss for the period   (7,254,429)   (3,842,861)
Items not requiring cash:          
Amortization and depreciation   78,329    64,797 
Share-based compensation   325,921    182,041 
Non-cash lease expense   126,080    61,065 
Loss on disposal of assets   11,355    - 
Interest income received on short-term investments   -    137 
Unrealized gain on derivative warrants liability   -    (242,628)
Unrealized foreign exchange loss   1,038    - 
Payments on lease obligations   (125,123)   (41,057)
Finance expense   -    360,350 
Changes in non-cash working capital:          
Inventories   (501,700)   - 
Prepaids and other assets   847,374    105,126 
Other non-current assets   6,030    (14,161)
Accounts receivable   (2,285)   (102,729)
Accounts payable and accrued liabilities   296,437    296,971 
Deferred revenue   3,248    - 
Total cash used in operating activities   (6,187,725)   (3,172,949)
           
Investing Activities          
Cash acquired from acquisition of BayMedica   91,566    - 
Purchase of property and equipment   (35,555)   - 
Total cash provided by investing activities   56,011    - 
           
Financing Activities          
Shares issued for cash   12,000,001    8,010,000 
Share issuance costs   (1,294,247)   (1,116,967)
Repayment of debt   (232,202)   - 
Settlement of debt upon acquisition of subsidiary   (425,000)   - 
Total cash provided by financing activities   10,048,552    6,893,033 
Effects of foreign exchange on cash and cash equivalents   -    494,960 
Increase in cash during the period   3,916,838    4,215,044 
Cash and cash equivalents beginning of the period   7,363,126    5,805,809 
Cash and cash equivalents end of the period   11,279,964    10,020,853 

 

8

 

 

Learn more about InMed’s Pharmaceutical Programs: https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/

 

Learn more about InMed’s Cannabinoid Manufacturing Capabilities: https://www.inmedpharma.com/manufacturing/cannabinoid-manufacturing-capabilities/

 

About InMed: InMed Pharmaceuticals is a global leader in the manufacturing and development of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

 

Investor Contact:

 

Colin Clancy

Senior Director, Investor Relations

T: +1 604 416 0999

E: cclancy@inmedpharma.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: the integration of BayMedica; accelerating the scale-up manufacturing of additional high demand cannabinoids; the commercial launch CBDV in the coming months and THCV in the second calendar quarter of 2022; meeting the needs of the health and wellness market sector; having sequential opportunities to achieve milestones across all aspects of the business; realizing substantial B2B revenue growth within the consumer health and wellness sector; leading the industry in manufacturing scale of CBC; initial production volumes of CBDV and THCV meeting anticipated market demand; CBGV and CBL being in various stages of development and commercial manufacturing scale-up; having flexibility to select the most cost-effective method to produce rare cannabinoids of interest; being able to produce high quality, bio-identical cannabinoids in a consistent manner for different target markets; being able to further optimize the IntegraSyn™ manufacturing process to be GMP and being able to produce larger batch sizes, and demonstrating larger-scale viability; IntegraSyn™ becoming a preferred method for pharmaceutical production; exploring other natural cannabinoids as well as proprietary cannabinoid analogs for future development; the 755-201-EB study including 13 sites across 8 countries with enrollment and patient treatment being completed during the calendar year 2022; the 755-201-EB study enrolling up to 20 patients to study the safety and preliminary efficacy of INM-755 (cannabinol) cream; having an INM-088 focused pre-Investigational New Drug meeting with the US Food and Drug Administration in the coming weeks; filing regulatory applications in the first half of calendar year 2023, to initiate a human clinical trial; producing a library of novel cannabinoid analogs and exploring their therapeutic potential; novel cannabinoid analogs improving selectivity in a therapeutic model, enhancing the safety profile, improving delivery, or combinations thereof, over naturally occurring cannabinoids;. being a global leader in the manufacturing and development of rare cannabinoids; and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

 

9

 

 

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

 

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Security and Exchange Commission on www.sec.gov.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

 

10

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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inm-20220214.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 inm-20220214_def.xml XBRL DEFINITION FILE EX-101.LAB 6 inm-20220214_lab.xml XBRL LABEL FILE Entity Addresses, Address Type [Axis] Former Address [Member] Entity Addresses [Table] Entity Addresses [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 inm-20220214_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Feb. 14, 2022
Entity Addresses [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 14, 2022
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One InMed Pharmaceuticals Inc.
Entity Address, Address Line Two Suite 310 - 815 W. Hastings Street
Entity Address, City or Town Vancouver, B.C.
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code (604)
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Former Address [Member]  
Entity Addresses [Line Items]  
Entity Address, Postal Zip Code 669-7207
XML 9 ea155719-8k_inmedpharma_htm.xml IDEA: XBRL DOCUMENT 0001728328 2022-02-14 2022-02-14 0001728328 dei:FormerAddressMember 2022-02-14 2022-02-14 iso4217:USD shares iso4217:USD shares 0001728328 false A1 8-K 2022-02-14 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 InMed Pharmaceuticals Inc. Suite 310 - 815 W. Hastings Street Vancouver, B.C. CA V6C 1B4 (604) 669-7207 669-7207 false false false false Common Shares, no par value INM NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( FJ3E0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " )JDY4K%R!*^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NLE@AZC+98@32$A, G&+$F^+:-(H,6KW]K1AZX3@ 3C&_O/Y ML^361&GZA,^ICYC(8;X9?1>R-''#CD11 F1S1*]S/27"U-SWR6N:GND 49L/ M?4 03;,&CZ2M)@TSL(H+D:G6&FD2:NK3&6_-@H^?J2LP:P []!@H Z\Y,#5/ MC*>Q:^$*F&&$R>?O MJ%6*I_8DL'V#DY9K>DAF&HAU7)33MP>'MZ?"GK5BYD MTL'@]"L[2:>(&W:9_+K:WN\>F!*-$%4C*GZW:X3D:\EOWV?7'WY78=];MW?_ MV/@BJ%KX=1?J"U!+ P04 " )JDY4F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M FJ3E0:,--PPP0 43 8 >&PO=V]R:W-H965T&UL MM9A=;^(X%(:OI[_"XFI&*I"8[Q%%HI1NT12&+;0C[6@O3&+ FL1F;:>T_WZ/ MPT?8F7#"KK2]*$G(>7ER?/P>Q]VMTC_,FG-+WN)(FIO2VMK-YVK5!&L>,U-1 M&R[AFZ72,;-PJE=5L]&(^(1#ZR38/#QR@<\BIP2'63##!RKZ)D*[OBFU2R3D2Y9$]DEM'_C^@1I.+U"12?^3 M[>[>AE6S^1/1K1_U: MJE\_HW^G@@1JR9+Y^X;G/2X>WBY_02#J1X@ZJM('@C"EN(_8*H\"CU^RR'"$ MHW'D:%R6C"G70H5D*$,"Q9.;%USI4 97'SX4%$+SR-9$%?>%<"\B3B9)O,@O M3ES#\_QRK=-L-Q">UI&G=0G/$U\)8S6#I$U8G)LI7&='%E?LM,M^G;9IJX/@^5[F?=XE@",9*+U1.F6[ M)C,+ MDNF:05L+>&)A6"+CTH 5HY]YN4__._%\JW*)<&KH?1IYU"1_W^9_)!^X,*F&NMC*7&I=[85!9"338:W);06>ZG_40 M'V\"OR#NBC27#E<:]#&@K)GX> _X&6BJC 43^D-LSD\<7/&E.2#^;1VCR]J) MC_>"= 3[L%X]#X,+?&QZ]4\82M9)?+P%/"J89C#KE,1:6X%(L]DIMZC7PHBR MMN'C;O]-"VNYA-3$<2+WYFQRJ7"AHI6)G[4,'W?XF8I$(-S$)F.P82U8E,N# MJQ3QT*Q%4-S$IYJ7 T@/EP'?+2!A#<)! O>4Z58&2JT\EKPC\S:!I<7 9 MJ3:=N[>=7%C\-PJG1-8"*.[> M;B,!YN9A0?1]S%T;P%YP:6;FM/V_O$+3S)OI1>OY?]/I"Q2Q;E8]V=1P&T1C MYFK/D(@O06QEO%DN7/ZZZ>S;"=I M=67=A['-HN6/O.-%Q[ MI#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4 M!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M. MB^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4 M?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_& M?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQ MY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7 M^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJ MOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T% M^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%N MXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI" M5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2 M='@//GL?)=-[*CG_5U/\!%!+ P04 " )JDY4EXJ[', 3 @ "P M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6= MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6' MTD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( FJ3E2JQ"(6,P$ M "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0 MI@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZF ML:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9 M$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R M#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROP MS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6 M= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4 M'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " )JDY4)!Z;HJT #X 0 &@ M 'AL+U]R96QS+W=O[IFBG#S^0W1UW6E\./VR M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/ M3K3G>1,)KM\,<'AT_@%02P,$% @ ":I.5&60>9(9 0 SP, M !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V + M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5 M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:> M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/] M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 M" )JDY4!T%-8H$ "Q $ @ $ 9&]C4')O<',O M87!P+GAM;%!+ 0(4 Q0 ( FJ3E2L7($K[@ "L" 1 M " :\ !D;V-0&UL M4$L! A0#% @ ":I.5!HPTW##! !1, !@ ("!#0@ M 'AL+W=O7!E&UL4$L%!@ ) D /@( %H4 ! $! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 2 122 1 false 1 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea155719-8k_inmedpharma.htm ea155719ex99-1_inmedpha.htm inm-20220214.xsd inm-20220214_def.xml inm-20220214_lab.xml inm-20220214_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea155719-8k_inmedpharma.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 2, "dts": { "definitionLink": { "local": [ "inm-20220214_def.xml" ] }, "inline": { "local": [ "ea155719-8k_inmedpharma.htm" ] }, "labelLink": { "local": [ "inm-20220214_lab.xml" ] }, "presentationLink": { "local": [ "inm-20220214_pre.xml" ] }, "schema": { "local": [ "inm-20220214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 64, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 1, "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20220214", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea155719-8k_inmedpharma.htm", "contextRef": "From2022-02-14to2022-02-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://inmedpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea155719-8k_inmedpharma.htm", "contextRef": "From2022-02-14to2022-02-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r14", "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r13", "r16" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r14": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r15": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r16": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308" }, "r17": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r18": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r19": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r20": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r21": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001213900-22-007757-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-007757-xbrl.zip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end